Epilepsy, antiepileptic drugs, and aggression: an evidence-based review

MJ Brodie, F Besag, AB Ettinger, M Mula, G Gobbi… - Pharmacological …, 2016 - Elsevier
Antiepileptic drugs (AEDs) have many benefits but also many side effects, including
aggression, agitation, and irritability, in some patients with epilepsy. This article offers a …

Agitation and dementia: prevention and treatment strategies in acute and chronic conditions

C Carrarini, M Russo, F Dono, F Barbone… - Frontiers in …, 2021 - frontiersin.org
Agitation is a behavioral syndrome characterized by increased, often undirected, motor
activity, restlessness, aggressiveness, and emotional distress. According to several …

Behavioral and psychological symptoms in Alzheimer's dementia and vascular dementia

WJ Deardorff, GT Grossberg - Handbook of clinical neurology, 2019 - Elsevier
Behavioral and psychological symptoms of dementia (BPSD) are highly prevalent and
represent a significant burden for patients and their caregivers. Early recognition and …

[HTML][HTML] Efficacy and safety of brexpiprazole for the treatment of agitation in Alzheimer's dementia: two 12-week, randomized, double-blind, placebo-controlled trials

GT Grossberg, E Kohegyi, V Mergel… - The American Journal of …, 2020 - Elsevier
Objective To assess the efficacy, safety, and tolerability of brexpiprazole in patients with
agitation in Alzheimer's dementia (AAD). Design Two 12-week, randomized, double-blind …

Understanding neuropsychiatric symptoms in Alzheimer's disease: challenges and advances in diagnosis and treatment

A Pless, D Ware, S Saggu, H Rehman… - Frontiers in …, 2023 - frontiersin.org
Neuropsychiatric symptoms (NPS) in Alzheimer's disease (AD) affect up to 97% of AD
patients, with an estimated 80% of current AD patients experiencing these symptoms …

Neuropsychiatric symptoms in dementia: considerations for pharmacotherapy in the USA

SV Phan, S Osae, JC Morgan, M Inyang, SC Fagan - Drugs in R&D, 2019 - Springer
Dementia affects all domains of cognition. The relentless progression of the disease after
diagnosis is associated with a 98% incidence of neuropsychiatric symptoms (NPS) at some …

The hyperactivity–impulsivity–irritiability–disinhibition–aggression–agitation domain in Alzheimer's disease: current management and future directions

RM Keszycki, DW Fisher, H Dong - Frontiers in pharmacology, 2019 - frontiersin.org
Behavioral and psychological symptoms of dementia (BPSD) afflict the vast majority of
patients with dementia, especially those with Alzheimer's disease (AD). In clinical settings …

Temporal lobe epilepsy and Alzheimer's disease: from preclinical to clinical evidence of a strong association

M Tombini, G Assenza, L Ricci… - Journal of …, 2021 - content.iospress.com
Increasing evidence coming from both experimental and humans' studies strongly suggest
the existence of a link between epilepsy, in particular temporal lobe epilepsy (TLE), and …

Safety and effectiveness of cannabinoids for the treatment of neuropsychiatric symptoms in dementia: a systematic review

JB Hillen, N Soulsby, C Alderman… - … advances in drug …, 2019 - journals.sagepub.com
Background: Neuropsychiatric symptoms (NPS) in dementia impact profoundly on the
quality of life of people living with dementia and their care givers. Evidence for the …

Gabapentin and pregabalin to treat aggressivity in dementia: a systematic review and illustrative case report

T Supasitthumrong… - British journal of …, 2019 - Wiley Online Library
Aims The prevalence of dementia is rising as life expectancy increases globally.
Behavioural and psychological symptoms of dementia (BPSD), including agitation and …